30/11/2020 – AB Science announces the signature of a 15.0 million financing deal with the European Investment Bank to support clinical development of masitinib in Covid-19 Download PDF Category: 2020By Alexis BERNARD30 November 2020Tags: capital Partager cet article Share on LinkedInShare on LinkedIn Share on XShare on X Share on FacebookShare on Facebook Share on WhatsAppShare on WhatsApp Pin itShare on Pinterest Author: Alexis BERNARD Post navigationPreviousPrevious post:Equity financing for a maximum of 4 million shares with Alpha Blue Ocean’s PACTNextNext post:Positive confirmatory Phase 3 study AB12005 with masitinib in first line pancreatic cancer with painRelated PostsBoursorama interview of Alain Moussy, CEO of AB Science23 December 2020Capital raise for a total amount of 15 million euros21 December 2020Results from phase 2B/3 study evaluating masitinib in Alzheimer’s disease18 December 2020Masitinib in Alzheimer’s Disease Webcast Presentation17 December 2020Results of the Extraordinary General Shareholders’ Meeting of December 16, 202017 December 2020Corrective press release regarding adverse events information from study AB0900417 December 2020
